Outcomes in COVID-19 MAS825 studies

0 0.5 1 1.5+ All studies -16% 1 138 Improvement, Studies, Patients Relative Risk Mortality -16% 1 138 RCTs -16% 1 138 Late -16% 1 138 MAS825 for COVID-19 c19early.org November 2025 FavorsMAS825 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] death 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] death 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -7% 1.07 [0.76-1.52] no recov. 68 (n) 70 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Late treatment -7% 1.07 [0.76-1.52] 68 (n) 70 (n) 7% higher risk All studies -7% 1.07 [0.76-1.52] 68 (n) 70 (n) 7% higher risk 1 MAS825 COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] death 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] death 26/68 23/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Late treatment -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk All studies -16% 1.16 [0.74-1.83] 26/68 23/70 16% higher risk 1 MAS825 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors MAS825 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MAS-COVID Hakim (DB RCT) -16% 1.16 [0.74-1.83] death 26/68 23/70 Improvement, RR [CI] Treatment Control MAS-COVID Hakim (DB RCT) -7% 1.07 [0.76-1.52] no recov. 68 (n) 70 (n) MAS825 COVID-19 outcomes c19early.org November 2025 Favors MAS825 Favors control